ACN - 101321555 Australasian Human Research Ethics Consultancy Services Pty Ltd (AHRECS)
Generic filters
Exact text matches only
Search into
Filter by Categories
Research integrity
Filter by Categories
Human Research Ethics

Resource Library

Research Ethics MonthlyAbout Us


Australasian Human Research Ethics Consultancy Services Pty Ltd (AHRECS)

(Australia) Caught Our Notice: Ethics, data concerns prompt another retraction for convicted researchers – Retraction Watch (Alison Abritis | November 2017)0

Posted by Admin in on November 4, 2017

Title: Unravelling the influence of mild traumatic brain injury (MTBI) on cognitive-linguistic processing: A comparative group analysis

What Caught our Attention: RW readers might already be familiar with Caroline Barwood and Bruce Murdoch, two researchers from Australia who had the rare distinction of being criminally charged for research misconduct. Both Barwood and Murdoch received suspended sentences after being found guilty of multiple counts of fraud. In September 2014, University of Queensland announcedthat:

“UQ subsequently examined 92 papers published since 2007 by former staff members Bruce Murdoch and Caroline Barwood. The examination did not reveal any other instances of research not supported by primary data or of research undertaken without ethics approval.

Read the rest of this discussion piece
Also see
(07/01/17) Remaining fraud charges withdrawn for Parkinson’s… – Retraction Watch
(9/11/16) Tougher action needed in the fight against… – The Conversation
(26/10/2016) Academic misconduct claims: Fresh call for national body – The Australian
(25/10/16) Parkinson’s researcher avoids jail following… – Retraction Watch
(24/10/16) Australian court finds Parkinson’s researcher guilty of fraud – Retraction Watch
(17/10/16) Parkinson’s researcher in Australia pleads not… – Retraction Watch
(14/10/16) Parkinson’s researcher with three retractions heads to court… – Retraction Watch

(21/07/16)  4th retraction for neuroscientist sentenced for fraud – Retraction Watch
(31/03/16) Bruce Murdoch: Former University of Queensland professor given suspended… – Courier Mail


Swedish review board finds misconduct by Macchiarini, calls for six retractions – Retraction Watch (Alison McCook | October 2017)0

Posted by Admin in on November 1, 2017

An ethical review board in Sweden is asking journals to retract six papers co-authored by former star surgeon Paolo Macchiarini, after concluding that he and his co-authors committed misconduct.

One of the papers is the seminal 2011 article in The Lancet, which described the first case of a transplant using an artificial trachea seeded with the patient’s own stem cells, and now bears an expression of concern from The Lancet editors. Over time, multiple authors have asked to be removed from the paper.

The Expert Group on Scientific Misconduct at the Central Ethical Review Board has determined that concerns over that paper — and five others co-authored by Macchiarini, once based at the Karolinska Institutet (KI) — were justified. In a press release, it says:

Read the rest of this news story
Also see
(29/09/2016) – Macchiarini scandal: overstepping the research ethics mark – Euroscientist
(01/09/2017) – Dr Con Man: the rise and fall of a celebrity scientist who fooled… – The Guardian

Released FDA docs reveal details of agency’s (failed) attempt to retract paper – Retraction Watch (Charles Seife | August 2017)0

Posted by Admin in on October 31, 2017

Earlier this year, a raging controversy regarding a new drug spilled into the pages of a leading medical journal: the head of the U.S. Food and Drug Administration and another official publicly called for the retraction or correction of a peer-reviewed article about the drug. They didn’t get their wish. Now, documents released by the FDA via alawsuit shed light on the attempt — and show how tricky it can be to correct the official record.

While a US case it highlights how hard it can sometimes be (even for the US FDA) to force a retraction.

The controversy surrounds the approval of eteplirsen, a drug approved last September to treat Duchenne Muscular Dystrophy, a rare but invariably fatal disease that strikes (mostly) young boys. Eteplirsen was approved over the objections of the FDA team that reviewed the drug, which determined that there was insufficient evidence to approve the drug.
But the controversy didn’t end within the walls of the FDA complex. Ellis Unger, who led the review team, believed that one of the principal studies of the drug, published in the Annals of Neurology, was “misleading” because it was based on “unreliable data.” So in early November, Unger, joined by the then-head of the FDA, Robert Califf, took the extremely rare move of writing to the editor of the journal to “urge that the paper be corrected or retracted….”

Read the rest of this discussion piece

University scandal, reputation and governance (Papers: Meredith Downes | 2017)0

Posted by Admin in on October 29, 2017


While about university scandal as opposed to research ethics scandals, this article provides insight to the impact of looming and actual scandal on university behaviours.

A review of the literature on corporate governance serves to demonstrate the applicability of many governance solutions to the university setting. Based on a review of university scandals, most of which are recent but some of which took place decades ago, it is possible to categorize them as follows: sex scandals, drugs, cheating, hazing, admissions and diplomas, on-the-job consumption, athletics, and murder. Several examples are provided in the paper, along with their impact on various stakeholders. The paper then discusses a variety of solutions designed to either preempt the activities potentially leading to scandal, to deter them or to punish perpetrators. Some of these involve structural changes, institutional policies and procedures, fines, terminations, and sanctions. The paper emphasizes the proactive safeguards which govern and monitor to make sure that universities do not suffer on the back end and that their reputations do not suffer into the future.


University reputation, University governance, Corporate governance, University scandal, Governance solutions, Governance in higher education

Downes, M (2017) University scandal, reputation and governance. International Journal for Educational Integrity 13(1): 8.
Publisher (open access):